https://newsletter.glp1studio.com/p/novos-investor-day-disappoints-asGLP-1 Studioen2026-09-24T17:00:00+00:00Novo's investor day disappoints as Lilly widens its leadhttps://newsletter.glp1studio.com/p/a-chinese-drugmakers-obesity-dataGLP-1 Studioen2026-09-24T17:00:00+00:00A Chinese drugmaker's obesity data will invite a semaglutide comparisonhttps://newsletter.glp1studio.com/p/amgens-next-glp-1-candidate-startsGLP-1 Studioen2026-09-23T17:00:00+00:00Amgen's next GLP-1 candidate starts its biggest human test yethttps://newsletter.glp1studio.com/p/cagrisemas-late-stage-weight-lossGLP-1 Studioen2026-09-23T17:00:00+00:00CagriSema's late-stage weight loss data lands as eye injury lawsuits mount